as 11-21-2024 4:00pm EST
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Founded: | 1994 | Country: | United States |
Employees: | N/A | City: | LEXINGTON |
Market Cap: | 96.2M | IPO Year: | 2000 |
Target Price: | $9.33 | AVG Volume (30 days): | 576.6K |
Analyst Decision: | Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -11.09 | EPS Growth: | N/A |
52 Week Low/High: | $2.50 - $19.69 | Next Earning Date: | 11-12-2024 |
Revenue: | $160,427,000 | Revenue Growth: | 59.00% |
Revenue Growth (this year): | -17.55% | Revenue Growth (next year): | 0.04% |
AGEN Breaking Stock News: Dive into AGEN Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Zacks
4 days ago
Zacks
7 days ago
Thomson Reuters StreetEvents
9 days ago
GuruFocus.com
9 days ago
Motley Fool
9 days ago
Zacks
10 days ago
Associated Press Finance
10 days ago
The information presented on this page, "AGEN Agenus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.